[ET Net News Agency, 27 March 2026] Nomura lowered the target price for Sino Biopharm
(01177) to HKD8.67 from HKD9.17 and maintained the "buy" rating.
The research house said it fine-tunes FY26F/FY27F topline by 1.9%/-1.6% and cuts
earnings estimates by 2.8%/7.3%. (rc)